Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI

Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI

Leucovorin-modulated 5-fluorouracil (5-FU) plus irinotecan (FOLFIRI) is the most common treatment of metastatic colorectal cancer (CRC). 5-FU inhibits thymidylate synthase (TS) and irinotecan topoisomerase I, leading to inhibition of DNA replication and repair. FOLFIRI efficacy suggested that other...

Full description

Bibliographic Details
Main Authors: Barcelos Ana, Giovannetti Elisa, de Jonge Robert, Maftouh Mina, Griffioen Pieter, Hanauske Axel R., Peters Godefridus J.
Format: Article
Language:English
Published: De Gruyter 2013-06-01
Series:Pteridines
Subjects:
5-fluorouracil
clinical outcome
colorectal cancer
pemetrexed
polymorphisms
Online Access:https://doi.org/10.1515/pterid-2013-0021

Internet

https://doi.org/10.1515/pterid-2013-0021

Similar Items